PUNE, India, April 8, 2016 /PRNewswire/ --
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes ALSP, Inc., Amarantus Bioscience Holdings, Inc., Athersys, Inc., BHR Pharma, LLC, Cognosci, Inc., Euroscreen S.A., Grupo Ferrer Internacional, S.A., Karyopharm Therapeutics, Inc., Kyorin Pharmaceutical Co., Ltd., Levolta Pharmaceuticals, Inc., Lixte Biotechnology Holdings, Inc., Lpath, Inc., Luc Therapeutics, Inc., MandalMed, Inc., Mapreg S.A.S., Neuralstem, Inc., Neuren Pharmaceuticals Limited, NeuroHealing Pharmaceuticals Inc., NeuroNascent, Inc., Neuronax SAS, NeuroVive Pharmaceutical AB, New World Laboratories, Inc., Novogen Limited, Omeros Corporation, PharmatrophiX, Inc., Phylogica Limited, Premier Biomedical Inc., Prevacus, Inc., QR Pharma, Inc., RegeneRx Biopharmaceuticals, Inc., Remedy Pharmaceuticals, Inc., Sage Therapeutics, Inc., SanBio, Inc., STATegics, Inc., Tetra Discovery Partners LLC, vasopharm GmbH and VG Life Sciences, Inc.
Complete report on H1 2016 pipeline review of Traumatic Brain Injury with 64 market data tables and 16 figures, spread across 255 pages is available at http://www.rnrmarketresearch.com/traumatic-brain-injury-pipeline-review-h1-2016-market-report.html .
Drugs Profiles discussed in this report includes (levocetirizine dihydrochloride + montelukast sodium), 2-DG, ALP-496, AMRS-001, ,apomorphine hydrochloride, AST-001, AST-002, AVL-8168, Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury, CHEC-7, CHEC-9, CNB-001, coenzyme Q10+ cyanocobalamin + cyclobenzaprine hydrochloride + naltrexone + pyridoxine, COG-1410, cyclosporine, dexamethasone acetate + melatonin, EPO-Variant, ESN-502, felbamate, FIB-117, glyburide, HBI-002, HBI-137, HBN-1, HBN-2, HPI-201, HPI-363, ibudilast, ICCN-100, JM-4, KPT-350, LB-201, LB-205, LM11A-31BHS, LM22A-4, Lpathomab, MAP-4343, Neu-2000, ND-478, NNI-370, NNZ-2591, NSI-189, NSI-566, NVP-019, NVX-428, NWL-53, NX-210, PF-05285401, Posiphen, progesterone, PRV-002, PYC-35, PYC-36, PYC-38, PYC-98, R-503, RGN-352, SB-623, sepranolone, Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury, Small Molecule to Antagonize GPR17 for CNS Disorders, Small Molecules for Stroke and Traumatic Brain Injury, Small Molecules for Traumatic Brain Injury, Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders, Small Molecules to Antagonize TLR-4 for CNS Disorders, Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases, Stem Cell Therapy for Central Nervous System Disorder, Stem Cell Therapy for CNS Disorders, STSE-15, T-094, TBI-121, TBI-122, TBI-123, trofinetide, UH-0113, UH-0213, VAS-203, VG-1177, VitalHeme and VOLT-02.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=522297 .
This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects.
Another newly published market research report titled on Seizures - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Seizures Pipeline market research 2016 report of 201 pages is available at http://www.rnrmarketresearch.com/seizures-pipeline-review-h1-2016-market-report.html .
Explore more reports on Neurology therapeutics.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
SOURCE RnR Market Research